TrialJournal of clinical pharmacology2017

A Novel NF-κB Inhibitor, Edasalonexent (CAT-1004), in Development as a Disease-Modifying Treatment for Patients With Duchenne Muscular Dystrophy: Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics in Adult Subjects.

Joanne M Donovan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.